Search

Your search keyword '"Nanjo, Shigeki"' showing total 216 results
Start Over Author "Nanjo, Shigeki"
216 results on '"Nanjo, Shigeki"'

1. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

Author

Caswell, Deborah R, Gui, Philippe, Mayekar, Manasi K, Law, Emily K, Pich, Oriol, Bailey, Chris, Boumelha, Jesse, Kerr, D Lucas, Blakely, Collin M, Manabe, Tadashi, Martinez-Ruiz, Carlos, Bakker, Bjorn, De Dios Palomino Villcas, Juan, I. Vokes, Natalie, Dietzen, Michelle, Angelova, Mihaela, Gini, Beatrice, Tamaki, Whitney, Allegakoen, Paul, Wu, Wei, Humpton, Timothy J, Hill, William, Tomaschko, Mona, Lu, Wei-Ting, Haderk, Franziska, Al Bakir, Maise, Nagano, Ai, Gimeno-Valiente, Francisco, de Carné Trécesson, Sophie, Vendramin, Roberto, Barbè, Vittorio, Mugabo, Miriam, Weeden, Clare E, Rowan, Andrew, McCoach, Caroline E, Almeida, Bruna, Green, Mary, Gomez, Carlos, Nanjo, Shigeki, Barbosa, Dora, Moore, Chris, Przewrocka, Joanna, Black, James RM, Grönroos, Eva, Suarez-Bonnet, Alejandro, Priestnall, Simon L, Zverev, Caroline, Lighterness, Scott, Cormack, James, Olivas, Victor, Cech, Lauren, Andrews, Trisha, Rule, Brandon, Jiao, Yuwei, Zhang, Xinzhu, Ashford, Paul, Durfee, Cameron, Venkatesan, Subramanian, Temiz, Nuri Alpay, Tan, Lisa, Larson, Lindsay K, Argyris, Prokopios P, Brown, William L, Yu, Elizabeth A, Rotow, Julia K, Guha, Udayan, Roper, Nitin, Yu, Johnny, Vogel, Rachel I, Thomas, Nicholas J, Marra, Antonio, Selenica, Pier, Yu, Helena, Bakhoum, Samuel F, Chew, Su Kit, Reis-Filho, Jorge S, Jamal-Hanjani, Mariam, Vousden, Karen H, McGranahan, Nicholas, Van Allen, Eliezer M, Kanu, Nnennaya, Harris, Reuben S, Downward, Julian, Bivona, Trever G, and Swanton, Charles

Subjects
Agricultural, Veterinary and Food Sciences, Biological Sciences, Bioinformatics and Computational Biology, Genetics, Agricultural Biotechnology, Biotechnology, Lung Cancer, Lung, Cancer, Women's Health, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Humans, Animals, Mice, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Up-Regulation, ErbB Receptors, Cytidine Deaminase, Minor Histocompatibility Antigens, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.

Published
2024

2. Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis

Author

Azad, Tej D., Nanjo, Shigeki, Jin, Michael C., Chabon, Jacob J., Kurtz, David M., Chaudhuri, Aadel A., Connolly, Ian D., Hui, Angela Bik-Yu, Liu, Chih Long, Merriott, David, Ko, Ryan, Yoo, Christopher, Carter, Justin, Chen, Emily, Bonilla, Rene, Hata, Akito, Katakami, Nobuyuki, Irie, Kei, Yano, Seiji, Okimoto, Ross, Bivona, Trever G., Newman, Aaron M., Iv, Michael, Nagpal, Seema, Gephart, Melanie Hayden, Alizadeh, Ash A., and Diehn, Maximilian

Published
2024
Full Text
View/download PDF

3. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

Author

Haderk, Franziska, Chou, Yu-Ting, Cech, Lauren, Fernández-Méndez, Celia, Yu, Johnny, Olivas, Victor, Meraz, Ismail M., Barbosa Rabago, Dora, Kerr, D. Lucas, Gomez, Carlos, Allegakoen, David V., Guan, Juan, Shah, Khyati N., Herrington, Kari A., Gbenedio, Oghenekevwe M., Nanjo, Shigeki, Majidi, Mourad, Tamaki, Whitney, Pourmoghadam, Yashar K., Rotow, Julia K., McCoach, Caroline E., Riess, Jonathan W., Gutkind, J. Silvio, Tang, Tracy T., Post, Leonard, Huang, Bo, Santisteban, Pilar, Goodarzi, Hani, Bandyopadhyay, Sourav, Kuo, Calvin J., Roose, Jeroen P., Wu, Wei, Blakely, Collin M., Roth, Jack A., and Bivona, Trever G.

Published
2024
Full Text
View/download PDF

4. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

Author

Nanjo, Shigeki, Wu, Wei, Karachaliou, Niki, Blakely, Collin M, Suzuki, Junji, Chou, Yu-Ting, Ali, Siraj M, Kerr, D Lucas, Olivas, Victor R, Shue, Jonathan, Rotow, Julia, Mayekar, Manasi K, Haderk, Franziska, Chatterjee, Nilanjana, Urisman, Anatoly, Yeo, Jia Chi, Skanderup, Anders J, Tan, Aaron C, Tam, Wai Leong, Arrieta, Oscar, Hosomichi, Kazuyoshi, Nishiyama, Akihiro, Yano, Seiji, Kirichok, Yuriy, Tan, Daniel SW, Rosell, Rafael, Okimoto, Ross A, and Bivona, Trever G

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung Cancer, Cancer, Rare Diseases, Genetics, Lung, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Aetiology, 2.1 Biological and endogenous factors, Apoptosis, Cell Line, Tumor, ErbB Receptors, Factor X, Humans, Lung Neoplasms, Protein Kinase Inhibitors, RNA Splicing Factors, RNA, Messenger, RNA-Binding Motifs, RNA-Binding Proteins, Cancer gene therapy, Lung cancer, Oncology, Therapeutics, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Molecularly targeted cancer therapy has improved outcomes for patients with cancer with targetable oncoproteins, such as mutant EGFR in lung cancer. Yet, the long-term survival of these patients remains limited, because treatment responses are typically incomplete. One potential explanation for the lack of complete and durable responses is that oncogene-driven cancers with activating mutations of EGFR often harbor additional co-occurring genetic alterations. This hypothesis remains untested for most genetic alterations that co-occur with mutant EGFR. Here, we report the functional impact of inactivating genetic alterations of the mRNA splicing factor RNA-binding motif 10 (RBM10) that co-occur with mutant EGFR. RBM10 deficiency decreased EGFR inhibitor efficacy in patient-derived EGFR-mutant tumor models. RBM10 modulated mRNA alternative splicing of the mitochondrial apoptotic regulator Bcl-x to regulate tumor cell apoptosis during treatment. Genetic inactivation of RBM10 diminished EGFR inhibitor-mediated apoptosis by decreasing the ratio of (proapoptotic) Bcl-xS to (antiapoptotic) Bcl-xL isoforms of Bcl-x. RBM10 deficiency was a biomarker of poor response to EGFR inhibitor treatment in clinical samples. Coinhibition of Bcl-xL and mutant EGFR overcame the resistance induced by RBM10 deficiency. This study sheds light on the role of co-occurring genetic alterations and on the effect of splicing factor deficiency on the modulation of sensitivity to targeted kinase inhibitor cancer therapy.

Published
2022

7. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts

Author

Quinn, Jeffrey J, Jones, Matthew G, Okimoto, Ross A, Nanjo, Shigeki, Chan, Michelle M, Yosef, Nir, Bivona, Trever G, and Weissman, Jonathan S

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lung, Cancer, Biotechnology, Lung Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, CRISPR-Cas Systems, Cell Line, Tumor, Cell Lineage, Clone Cells, Gene Expression Regulation, Neoplastic, Humans, Keratin-17, Lung Neoplasms, Mice, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Seeding, Neoplasm Transplantation, Phenotype, RNA-Seq, Single-Cell Analysis, Transcriptome, Transplantation, Heterologous, General Science & Technology
Abstract

Detailed phylogenies of tumor populations can recount the history and chronology of critical events during cancer progression, such as metastatic dissemination. We applied a Cas9-based, single-cell lineage tracer to study the rates, routes, and drivers of metastasis in a lung cancer xenograft mouse model. We report deeply resolved phylogenies for tens of thousands of cancer cells traced over months of growth and dissemination. This revealed stark heterogeneity in metastatic capacity, arising from preexisting and heritable differences in gene expression. We demonstrate that these identified genes can drive invasiveness and uncovered an unanticipated suppressive role for KRT17 We also show that metastases disseminated via multidirectional tissue routes and complex seeding topologies. Overall, we demonstrate the power of tracing cancer progression at subclonal resolution and vast scale.

Published
2021

8. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs

Author

Okimoto, Ross A, Wu, Wei, Nanjo, Shigeki, Olivas, Victor, Lin, Yone K, Ponce, Rovingaile Kriska, Oyama, Rieko, Kondo, Tadashi, and Bivona, Trever G

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biotechnology, Rare Diseases, Orphan Drug, Pediatric Research Initiative, Infectious Diseases, Genetics, Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, Carcinogenesis, Cell Line, Tumor, Cyclin E, Cyclin-Dependent Kinase 2, Female, Humans, Mice, Mice, SCID, Neoplasm Metastasis, Neoplasms, Experimental, Oncogene Proteins, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-ets, Sarcoma, Transcription, Genetic, Molecular genetics, Oncology, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Transcription factor fusion genes create oncoproteins that drive oncogenesis and represent challenging therapeutic targets. Understanding the molecular targets by which such fusion oncoproteins promote malignancy offers an approach to develop rational treatment strategies to improve clinical outcomes. Capicua-double homeobox 4 (CIC-DUX4) is a transcription factor fusion oncoprotein that defines certain undifferentiated round cell sarcomas with high metastatic propensity and poor clinical outcomes. The molecular targets regulated by the CIC-DUX4 oncoprotein that promote this aggressive malignancy remain largely unknown. We demonstrated that increased expression of ETS variant 4 (ETV4) and cyclin E1 (CCNE1) occurs via neomorphic, direct effects of CIC-DUX4 and drives tumor metastasis and survival, respectively. We uncovered a molecular dependence on the CCNE-CDK2 cell cycle complex that renders CIC-DUX4-expressing tumors sensitive to inhibition of the CCNE-CDK2 complex, suggesting a therapeutic strategy for CIC-DUX4-expressing tumors. Our findings highlight a paradigm of functional diversification of transcriptional repertoires controlled by a genetically aberrant transcriptional regulator, with therapeutic implications.

Published
2019

9. Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.

Author

Sato, Yuki, Sato, Yoshiharu, Irie, Kei, Nanjo, Shigeki, Hara, Shigeo, Fujiwara, Satoru, and Tomii, Keisuke

Subjects
ADENOCARCINOMA, PROTEIN kinase inhibitors, DRUG resistance in cancer cells, EPITHELIAL-mesenchymal transition, CENTRAL nervous system, METASTASIS, GENES, ANAPLASTIC lymphoma kinase, DRUG efficacy, LUNG cancer, GENETIC mutation, BRAIN tumors, SEQUENCE analysis, DISEASE progression, PHARMACODYNAMICS
Abstract

We present the case of a 34‐year‐old Japanese man with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with lorlatinib resulted in a good intracranial response. In this case, we investigated brain penetration ratio of brigatinib using cerebrospinal fluid and paired serum samples, and the ratio was 0.012. Further, we investigated resistance mechanisms via next‐generation sequencing (NGS) using lung biopsy at lung cancer diagnosis and brain biopsy sample at progressive disease of brigatinib. No apparent resistance mechanism of known ALK resistance, such as ALK mutations, amplifications, epithelial‐mesenchymal transition (EMT) and bypass pathway activation were detected. Taken together, we speculate that the low CNS penetration rate of brigatinib confers CNS progression. Further studies are warranted to reveal the resistance mechanism and propose a treatment strategy for CNS progression in ALK‐positive patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis

Author

Azad, Tej D., primary, Nanjo, Shigeki, additional, Jin, Michael C., additional, Chabon, Jacob J., additional, Kurtz, David M., additional, Chaudhuri, Aadel A., additional, Connolly, Ian D., additional, Hui, Angela Bik-Yu, additional, Liu, Chih Long, additional, Merriott, David, additional, Ko, Ryan, additional, Yoo, Christopher, additional, Carter, Justin, additional, Chen, Emily, additional, Bonilla, Rene, additional, Hata, Akito, additional, Katakami, Nobuyuki, additional, Irie, Kei, additional, Yano, Seiji, additional, Okimoto, Ross, additional, Bivona, Trever G., additional, Newman, Aaron M., additional, Iv, Michael, additional, Nagpal, Seema, additional, Gephart, Melanie Hayden, additional, Alizadeh, Ash A., additional, and Diehn, Maximilian, additional

Published
2024
Full Text
View/download PDF

11. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer

Author

Arai, Sachiko, Takeuchi, Shinji, Fukuda, Koji, Taniguchi, Hirokazu, Nishiyama, Akihiro, Tanimoto, Azusa, Satouchi, Miyako, Yamashita, Kaname, Ohtsubo, Koshiro, Nanjo, Shigeki, Kumagai, Toru, Katayama, Ryohei, Nishio, Makoto, Zheng, Mei-mei, Wu, Yi-Long, Nishihara, Hiroshi, Yamamoto, Takushi, Nakada, Mitsutoshi, and Yano, Seiji

Published
2020
Full Text
View/download PDF

12. Brain mimetic co-culture experiments identify mGluR1 dependence as a vulnerability of lung cancer brain metastasis

Author

Hirata, Eishu, primary, Ishibashi, Kojiro, additional, Ichinose, Toshiya, additional, Kadokawa, Riki, additional, Mizutani, Ryo, additional, Iwabuchi, Sadahiro, additional, Togi, Sumihito, additional, Ura, Hiroki, additional, Shinjo, Keiko, additional, Nakayama, Jun, additional, Nanjo, Shigeki, additional, Niida, Yo, additional, Kondo, Yutaka, additional, Hashimoto, Shinichi, additional, Sahai, Erik, additional, Yano, Seiji, additional, and Nakada, Mitsutoshi, additional

Published
2023
Full Text
View/download PDF

13. Supplementary Figure Legend from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 1 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 5 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 6 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

19. Data from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 2 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 3 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 4 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Author

Nakagawa, Takayuki, primary, Takeuchi, Shinji, primary, Yamada, Tadaaki, primary, Nanjo, Shigeki, primary, Ishikawa, Daisuke, primary, Sano, Takako, primary, Kita, Kenji, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Suda, Kenichi, primary, Mitsudomi, Tetsuya, primary, Sekido, Yoshitaka, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

25. Data from Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

Author

Fukuda, Koji, primary, Takeuchi, Shinji, primary, Arai, Sachiko, primary, Katayama, Ryohei, primary, Nanjo, Shigeki, primary, Tanimoto, Azusa, primary, Nishiyama, Akihiro, primary, Nakagawa, Takayuki, primary, Taniguchi, Hirokazu, primary, Suzuki, Takeshi, primary, Yamada, Tadaaki, primary, Nishihara, Hiroshi, primary, Ninomiya, Hironori, primary, Ishikawa, Yuichi, primary, Baba, Satoko, primary, Takeuchi, Kengo, primary, Horiike, Atsushi, primary, Yanagitani, Noriko, primary, Nishio, Makoto, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

26. Supplemental materials and methods from Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

Author

Fukuda, Koji, primary, Takeuchi, Shinji, primary, Arai, Sachiko, primary, Katayama, Ryohei, primary, Nanjo, Shigeki, primary, Tanimoto, Azusa, primary, Nishiyama, Akihiro, primary, Nakagawa, Takayuki, primary, Taniguchi, Hirokazu, primary, Suzuki, Takeshi, primary, Yamada, Tadaaki, primary, Nishihara, Hiroshi, primary, Ninomiya, Hironori, primary, Ishikawa, Yuichi, primary, Baba, Satoko, primary, Takeuchi, Kengo, primary, Horiike, Atsushi, primary, Yanagitani, Noriko, primary, Nishio, Makoto, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures 1 - 3 from Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Author

Yamada, Tadaaki, primary, Takeuchi, Shinji, primary, Nakade, Junya, primary, Kita, Kenji, primary, Nakagawa, Takayuki, primary, Nanjo, Shigeki, primary, Nakamura, Takahiro, primary, Matsumoto, Kunio, primary, Soda, Manabu, primary, Mano, Hiroyuki, primary, Uenaka, Toshimitsu, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

28. FigureS1-S9, TableS1 from Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

Author

Fukuda, Koji, primary, Takeuchi, Shinji, primary, Arai, Sachiko, primary, Katayama, Ryohei, primary, Nanjo, Shigeki, primary, Tanimoto, Azusa, primary, Nishiyama, Akihiro, primary, Nakagawa, Takayuki, primary, Taniguchi, Hirokazu, primary, Suzuki, Takeshi, primary, Yamada, Tadaaki, primary, Nishihara, Hiroshi, primary, Ninomiya, Hironori, primary, Ishikawa, Yuichi, primary, Baba, Satoko, primary, Takeuchi, Kengo, primary, Horiike, Atsushi, primary, Yanagitani, Noriko, primary, Nishio, Makoto, primary, and Yano, Seiji, primary

Published
2023
Full Text
View/download PDF

32. A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA

Author

Zhang, Bin, primary, Liang, Han, additional, Liu, Weiran, additional, Zhou, Xinlan, additional, Qiao, Sitan, additional, Li, Fuqiang, additional, Tian, Pengfei, additional, Li, Chenguang, additional, Ma, Yuchen, additional, Zhang, Hua, additional, Zhang, Zhenfa, additional, Nanjo, Shigeki, additional, Russo, Alessandro, additional, Puig-Butillé, Joan Anton, additional, Wu, Kui, additional, Wang, Changli, additional, Zhao, Xin, additional, and Yue, Dongsheng, additional

Published
2022
Full Text
View/download PDF

35. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Author

Hata, Akito, Katakami, Nobuyuki, Fujita, Shiro, Nanjo, Shigeki, Takeshita, Jumpei, Tanaka, Kosuke, Kaneda, Toshihiko, Nishiyama, Akihiro, Nishimura, Takashi, Nakagawa, Atsushi, Otsuka, Kojiro, Morita, Satoshi, Urata, Yoshiko, and Negoro, Shunichi

Published
2015
Full Text
View/download PDF

36. A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Author

Haderk, Franziska, primary, Fernández-Méndez, Celia, additional, Čech, Lauren, additional, Yu, Johnny, additional, Meraz, Ismail M., additional, Olivas, Victor, additional, Rabago, Dora Barbosa, additional, Lucas Kerr, D., additional, Gomez, Carlos, additional, Allegakoen, David V., additional, Guan, Juan, additional, Shah, Khyati N., additional, Herrington, Kari A., additional, Gbenedio, Oghenekevwe M., additional, Nanjo, Shigeki, additional, Majidi, Mourad, additional, Tamaki, Whitney, additional, Rotow, Julia K., additional, McCoach, Caroline E., additional, Riess, Jonathan W., additional, Silvio Gutkind, J., additional, Tang, Tracy T., additional, Post, Leonard, additional, Huang, Bo, additional, Santisteban, Pilar, additional, Goodarzi, Hani, additional, Bandyopadhyay, Sourav, additional, Kuo, Calvin J., additional, Roose, Jeroen P., additional, Wu, Wei, additional, Blakely, Collin M., additional, Roth, Jack A., additional, and Bivona, Trever G., additional

Published
2021
Full Text
View/download PDF

39. Abstract LB124: APOBEC3B fuels evolution of resistance during targeted cancer therapy

Author

Mayekar, Manasi K., primary, Caswell, Deborah, additional, Vokes, Natalie, additional, Wu, Wei, additional, McCoach, Caroline, additional, Blakely, Collin, additional, Temiz, Nuri Alpay, additional, Kerr, Daniel Lucas, additional, Rotow, Julia, additional, Haderk, Franziska, additional, Cech, Lauren, additional, Gini, Beatrice, additional, Nanjo, Shigeki, additional, Tan, Lisa, additional, Yu, Johnny, additional, Gomez, Carlos, additional, Gui, Philippe, additional, Yu, Elizabeth, additional, Thomas, Nicholas, additional, Downward, Julian, additional, Harris, Reuben, additional, Van Allen, Eliezer, additional, Swanton, Charles, additional, and Bivona, Trever, additional

Published
2021
Full Text
View/download PDF

41. Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)

Author

Izumi, Kouji, primary, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Nohara, Takahiro, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Nanjo, Shigeki, additional, Yamada, Tadaaki, additional, Ohtsubo, Koshiro, additional, Yano, Seiji, additional, and Mizokami, Atsushi, additional

Published
2021
Full Text
View/download PDF

42. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations

Author

Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko, Imai, Yukihiro, Monden, Kazuya, Matsumoto, Takeshi, Nagata, Kazuma, Otsuka, Kyoko, Tachikawa, Ryo, Tomii, Keisuke, Kunimasa, Kei, Iwasaku, Masahiro, Nishiyama, Akihiro, Ishida, Tadashi, and Nishimura, Yoshihiro

Published
2013
Full Text
View/download PDF

43. Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

Author

Mayekar, Manasi K., primary, Caswell, Deborah R., additional, Vokes, Natalie I., additional, Law, Emily K., additional, Wu, Wei, additional, Hill, William, additional, Gronroos, Eva, additional, Rowan, Andrew, additional, Al Bakir, Maise, additional, McCoach, Caroline E., additional, Blakely, Collin M., additional, Temiz, Nuri Alpay, additional, Nagano, Ai, additional, Kerr, D. Lucas, additional, Rotow, Julia K., additional, Haderk, Franziska, additional, Dietzen, Michelle, additional, Ruiz, Carlos Martinez, additional, Almeida, Bruna, additional, Cech, Lauren, additional, Gini, Beatrice, additional, Przewrocka, Joanna, additional, Moore, Chris, additional, Murillo, Miguel, additional, Bakker, Bjorn, additional, Rule, Brandon, additional, Durfee, Cameron, additional, Nanjo, Shigeki, additional, Tan, Lisa, additional, Larson, Lindsay K., additional, Argyris, Prokopios P., additional, Brown, William L., additional, Yu, Johnny, additional, Gomez, Carlos, additional, Gui, Philippe, additional, Vogel, Rachel I., additional, Yu, Elizabeth A., additional, Thomas, Nicholas J., additional, Venkatesan, Subramanian, additional, Hobor, Sebastijan, additional, Chew, Su Kit, additional, Kanu, Nnennaya, additional, McGranahan, Nicholas, additional, Van Allen, Eliezer M., additional, Downward, Julian, additional, Harris, Reuben S., additional, Bivona, Trever G., additional, and Swanton, Charles, additional

Published
2020
Full Text
View/download PDF

44. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

Author

Nanjo, Shigeki, primary, Wu, Wei, additional, Karachaliou, Niki, additional, Blakely, Collin M., additional, Suzuki, Junji, additional, Ali, Siraj, additional, Kerr, D. Lucas, additional, Olivas, Victor, additional, Shue, Jonathan, additional, Rotow, Julia, additional, Mayekar, Manasi, additional, Haderk, Franziska, additional, Chatterjee, Nilanjana, additional, Urisman, Anatoly, additional, Kirichok, Yuriy, additional, Tan, Daniel S. W., additional, Rosell, Rafael, additional, Okimoto, Ross A, additional, and Bivona, Trever G., additional

Published
2020
Full Text
View/download PDF

47. A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer

Author

Kaushik, Swati, primary, Haderk, Franziska, additional, Zhao, Xin, additional, Hu, Hsien-Ming, additional, Shah, Khyati N., additional, Jang, Gwendolyn M., additional, Olivas, Victor, additional, Nanjo, Shigeki, additional, Jascur, John, additional, Masto, Vincent B., additional, Ciznadija, Daniel, additional, Sloma, Ido, additional, Gross, Emilie, additional, Weinrich, Scott L., additional, Johnson, Jeffery R., additional, Bivona, Trever G., additional, Krogan, Nevan J., additional, and Bandyopadhyay, Sourav, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results